Hadassah Medical Organization - Product Pipeline Review - Q4 2010

Hadassah Medical Organization - Product Pipeline Review - Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Hadassah Medical Organization - Developmental Therapeutics Review - Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

• Review of therapeutics under development by Hadassah Medical Organization.
• Overview of products under development across various therapy areas.
• Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of Hadassah Medical Organization with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of Hadassah Medical Organization’s therapeutic products in the last quarter.
• Latest news and deals relating to the products.

Reasons to buy

• Identify new drug targets and therapeutic classes in Hadassah Medical Organization’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
• Evaluate Hadassah Medical Organization’s position with total access to a detailed information on its therapeutic products development.
• Assess the growth potential of Hadassah Medical Organization in its therapy areas of focus.
• Exploit collaboration and partnership opportunities with Hadassah Medical Organization.
• Avoid Intellectual Property Rights related issues.